{
    "clinical_study": {
        "@rank": "75701", 
        "acronym": "AML", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5).  Rapamycin 6mg (loading dose) will be administered on day 6; thereafter 2 mg/day on days 11-22 in cycle 1 and on days 6-22 in subsequent cycles. (Arm A: for patients with non-morphologic M4/M5 subtypes)."
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Experimental", 
                "description": "Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Ribavirin will be dosed from day 11-day 28 beginning with dose level 1 (1000mg orally twice daily).  Number of patients with Dose Limiting Toxicities (DLT) at a given dose level is 0 of out of 3: enter 3 patients at the next dose level (dose Level 2- 1200mg orally twice daily; and then dose Level 3-1400 mg orally twice daily).(Arm B: For patients with morphologic M4/M5 subtypes)."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the response to chemotherapy with the drug decitabine combined with rapamycin in\n      the treatment of relapsed or refractory acute myeloid leukemia in patients of all ages, and\n      in the treatment of newly diagnosed leukemia in those who are older than 65 when diagnosed."
        }, 
        "brief_title": "Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myelogenous Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "To determine the efficacy of decitabine followed by Rapamycin in previously untreated\n      elderly patients not able to receive standard chemotherapy or in patients with relapsed or\n      refractory AML, through measurement of Complete Remission (CR), Complete Remission\n      Incomplete Platelet Recovery (CRp), Partial Remission (PR), and event free and overall\n      survival (Arm A).\n\n      To determine the safety of administration of decitabine with escalating doses of Ribavirin\n      in elderly leukemia patients or patients with relapsed/refractory disease with M4/M5\n      subtypes anticipated to express high eukaryotic translation initiation factor 4E (eIF4E) at\n      diagnosis (Arm B).\n\n      To establish effect of these sequential treatments on expression of phosphoinositide\n      3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt /mTOR) pathway proteins\n      and on eukaryotic translation initiation factor 4E (eIF4E) activation through Western blot\n      and phospho-flow methodologies.\n\n      To correlate the clinical response with baseline expression of phospho-p70S6\n      Kinase/phosphorylated protein kinase B (pAKT) and with the in vitro inhibitory effects of\n      mammalian target of rapamycin (mTOR) inhibition with rapamycin or ribavirin on the level of\n      downstream effectors.\n\n      To determine whether a leukemia stem cell phenotype is inhibited by the sequential\n      administration of decitabine/rapamycin or decitabine/ribavirin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        4.1.1  Age >/= 18 4.1.2  Diagnosis of AML according to World Health Organization (WHO)\n        criteria  except acute promyelocytic leukemia AND 4.1.3  Refractory AML defined as failure\n        to achieve Complete Remission (CR) after 2 cycles of  induction chemotherapy or\n        persistence of > 40% bone marrow blasts after one cycle of chemotherapy induction OR 4.1.4\n         Relapsed AML defined as any evidence of disease recurrence after achieving a documented\n        first or greater Complete Remission (CR) OR 4.1.5  Relapsed AML after stem cell\n        transplantation. 90 days (since stem cell infusion) must have elapsed between transplant\n        and emergence of recurrent AML OR 4.1.6  Newly diagnosed AML in a patient >65 years old\n        not considered fit for standard 7+ 3 chemotherapy or who declines such therapy after\n        discussion of therapeutic options available.\n\n        4.1.7 Eastern Cooperative Oncology Group (ECOG)  performance status <3\n\n        Exclusion Criteria:\n\n        4.2.1  Abnormal renal function as evidenced by a calculated creatinine clearance \u2264 30\n        ml/min (Cockcroft-Gault formula (Appendix 2) 4.2.2 Abnormal liver function: Bilirubin >2.0\n        mg/dl, transaminase(s) more than  2.5x the upper limits of normal 4.2.3 Active systemic\n        infection not responding to antibiotics 4.2.4 Known diagnosis of human immunodeficiency\n        virus infection (HIV) 4.2.5 Patients who are post-allogeneic transplantation should not\n        have active Graft vs. Host Disease (GVHD) greater than grade 1 of skin at time of\n        enrollment.  They may have had donor lymphocyte infusion (DLI) but not within 4 weeks of\n        beginning the study.\n\n        4.2.6 Pregnant or breastfeeding female subjects 4.2.7 Known or suspected Central Nervous\n        System (CNS) leukemia involvement; past involvement is not an exclusion.\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109744", 
            "org_study_id": "48721", 
            "secondary_id": "ULEU13049"
        }, 
        "intervention": {
            "arm_group_label": [
                "A", 
                "B"
            ], 
            "intervention_name": "Decitabine", 
            "intervention_type": "Drug", 
            "other_name": [
                "Dacogen", 
                "5-aza-2'-deoxycytidine"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Decitabine", 
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "contact": {
                "email": "Jessica_Mavor@urmc.rochester.edu", 
                "last_name": "Jessica Mavor", 
                "phone": "585-275-5485"
            }, 
            "contact_backup": {
                "email": "Robin_Boerman@urmc.rochester.edu", 
                "last_name": "Robin Boerman", 
                "phone": "585-273-1507"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14642"
                }, 
                "name": "University of Rochester"
            }, 
            "investigator": [
                {
                    "last_name": "Jane Liesveld, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Kristen O'Dwyer, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I/II Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients", 
        "overall_contact": {
            "email": "Jane_Liesveld@urmc.rochester.edu", 
            "last_name": "Jane Liesveld, MD", 
            "phone": "585-275-5823"
        }, 
        "overall_official": {
            "affiliation": "University of Rochester", 
            "last_name": "Jane Liesveld, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Data and Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "bone marrow aspirate and biopsy exam", 
            "measure": "change in blast percentage in the bone marrow", 
            "safety_issue": "No", 
            "time_frame": "four weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109744"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Complete blood count with differential.", 
            "measure": "change in blast percentage in peripheral blood", 
            "safety_issue": "No", 
            "time_frame": "four weeks"
        }, 
        "source": "University of Rochester", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Rochester", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}